Table 1 Associations between the subjects’ demographics and APOE E4 and E2 variants
From: APOE – a genetic marker of comorbidity in subjects with morbid obesity
Subject demographics (no is given if less than 140) | APOE-E4 Present (no 55) | APOE-E4 Absent (no 85) | Statistics p-value | Adjusted* p-value | APOE-E2 Present (no 18) | APOE-E2 Absent (no 122) | Statistics p-value | Adjusted* p-value |
|---|---|---|---|---|---|---|---|---|
Gender (female) | 43/55 (78%) | 65/85 (76%) | p = 0.84 | 13/18 (72%) | 95/122 (78%) | 0.76 | ||
Age (years) | 42.6 (9.5) | 43.3 (8.1) | P = 0.68 | 41.8 (8.4) | 43.2 (8.7) | 0.53 | ||
Body weight (kg) | 124.5 (19.3) | 123.3 (18.4) | P = 0.72 | 126.2 (20.7) | 123.4 (18.4) | 0.56 | ||
Height (cm) | 171.6 (9.6) | 170.7 (8.5) | P = 0.59 | 172.2 (9.2) | 170.9 (8.9) | 0.58 | ||
BMI (kg / m2) | 42.1 (4.0) | 42.1 (3.7) | P = 0.99 | −0.07 (−1.26;1.13) p = 0.91 ** | 42.4 (4.9) | 42.1 (3.6) | 0.73 | 0.00 (− 1.74; 1.74) p = 1.00 ** |
BMI reduction during the first treatment period (no 95) | 3.2 (1.6) | 2.9 (1.5) | P = 0.28 | 0.34 (−0.21; 0.98) p = 0.30 | 2.7 (1.4) | 3.1 (1.6) | 0.48 | −0.28 (−1.22;0.66) P = 0.56 |
BMI reduction during the last treatment period (no 92) | 11.0 (3.7) | 10.5 (3.2) | P = 0.46 | 0.94 (−0.37;2.25) p = 0.16 | 10.0 (4.5) | 10.8 (3.2) | 0.44 | −0.41 (−2.30;1.48) p = 0.67 |
BMI reduction total (no 92) | 14.3 (3.8) | 13.4 (3.5) | P = 0.21 | 1.36 (−0.04;2.75) p = 0.057 | 12.7 (5.1) | 13.9 (3.3) | 0.45 | −0.72 (−2.76;1.32) p = 0.49 |